CAR T-cell therapy — long a powerhouse in blood cancer treatment — may be getting a meaningful upgrade for autoimmune neurologic diseases. A phase 1 trial published in the New England Journal of Medicine tested JY231, an off-the-shelf lentiviral vector that generates CAR T cells directly inside the patient's body, bypassing the costly and complex process of extracting, engineering, and reinfusing a patient's own cells. All 16 participants — spanning MS, MOGAD, myasthenia gravis, and inflammatory myopathies — produced functional CAR T cells in vivo and showed B-cell depletion along with disease-specific clinical improvements at 6 months, without requiring lymphodepleting chemotherapy.

The approach is notable because the vector appears to cross the blood-brain barrier, reaching compartments like cerebrospinal fluid and bone marrow that traditional B-cell-depleting drugs like rituximab cannot. Experts praised the engineering innovation but urged caution: disability improvements in progressive MS are difficult to attribute to inflammation control alone, and residual memory B cells suggest the "immunologic reset" may be incomplete.

Key Takeaways:

• JY231 eliminated the need for ex vivo cell manufacturing and lymphodepletion, potentially making CAR T more scalable and accessible
• Grade 1 cytokine release syndrome occurred in 69% of patients but resolved within 2 weeks; no neurotoxicity was observed
• The vector achieved higher copy numbers in CSF than in peripheral blood, suggesting CNS penetration — a key advantage over existing therapies

Why it matters: If validated in larger, controlled trials, in vivo CAR T could lower the barrier to a therapy that currently costs hundreds of thousands of dollars, offering a potential one-time treatment option for patients with refractory neurologic autoimmune diseases.